- Home
- SGLY vs CMND Comparison
SGLY vs CMND Comparison
Compare SGLY & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | CMND |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.6M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGLY | CMND |
|---|---|---|
| Price | $0.40 | $2.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.7K | ★ 2.6M |
| Earning Date | 05-15-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,813,193.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.07 |
| 52 Week High | $1.45 | $4.66 |
Technical Indicators
Market Signals| Indicator | SGLY | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 69.29 |
| Support Level | $0.37 | $0.31 |
| Resistance Level | $0.43 | N/A |
| Average True Range (ATR) | 0.03 | 0.37 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 36.64 | 61.71 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.